CD22 Antibody (OX97): sc-53032
- CD22 Antibody (OX97) is a rat monoclonal IgG1 provided at 200 µg/ml
- raised against CD22 of mouse origin
- recommended for detection of domain 2 of cell surface glycoprotein CD22 of mouse origin by FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD22 Antibody (OX97). This work is in progress.
QUICK LINKS
SEE ALSO...
CD22 Antibody (OX97) is a rat monoclonal IgG1 antibody that detects CD22 in mouse samples through flow cytometry (FCM). CD22 is a crucial B lymphocyte-specific antigen, also known as the B-lymphocyte cell adhesion molecule (BLCAM), sialic acid-binding Ig-like lectin 2 (Siglec-2), and Leu-14. This type I integral membrane glycoprotein plays a vital role in regulating B cell signaling, which is essential for maintaining immune homeostasis and preventing autoimmune responses. CD22 is expressed in both cytoplasmic and membrane forms during various stages of B cell differentiation, with the cytoplasmic variant serving as a significant marker for acute lymphocytic leukemia, particularly in early B cell development. The membrane form is predominantly found in mature B cells before differentiation into plasma cells, highlighting CD22′s importance in the maturation process. Alternative splicing of the CD22 gene results in two isoforms, CD22α and CD22β, with CD22β being the principal isoform. CD22 can exist as a heterodimer composed of CD22β and the shorter isoform, CD22α, which may influence functional interactions and signaling pathways. Anti-CD22 antibody (OX97) is an invaluable tool for researchers studying B cell biology and related pathologies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD22 Antibody (OX97) References:
- A reevaluation of CD22 expression in human lung cancer. | Pop, LM., et al. 2014. Cancer Res. 74: 263-71. PMID: 24395821
- The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. | Dörner, T., et al. 2015. Autoimmun Rev. 14: 1079-86. PMID: 26212727
- Molecular basis of human CD22 function and therapeutic targeting. | Ereño-Orbea, J., et al. 2017. Nat Commun. 8: 764. PMID: 28970495
- Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. | Yurkiewicz, IR., et al. 2018. Drug Des Devel Ther. 12: 2293-2300. PMID: 30087554
- A CD22-Shp1 phosphatase axis controls integrin β7 display and B cell function in mucosal immunity. | Ballet, R., et al. 2021. Nat Immunol. 22: 381-390. PMID: 33589816
- The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45-/- immunodeficient B cells. | Akatsu, C., et al. 2022. Sci Signal. 15: eabf9570. PMID: 35230871
- Characterization of the immune regulatory property of CD22+ CD9+ B cells. | Yang, G., et al. 2022. Immunology. 167: 328-339. PMID: 35754150
- A Novel Anti-CD22 scFv.Bim Fusion Protein Effectively Induces Apoptosis in Malignant B cells and Promotes Cytotoxicity. | Mohammadi, Z., et al. 2022. Appl Biochem Biotechnol. 194: 5878-5906. PMID: 35838885
- Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy. | Zaib, T., et al. 2023. Int J Mol Sci. 24: PMID: 36768478
- CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia. | Jin, X., et al. 2024. Haematologica. 109: 3004-3008. PMID: 38695137
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD22 Antibody (OX97) | sc-53032 | 200 µg/ml | $322.00 | |||
CD22 Antibody (OX97) FITC | sc-53032 FITC | 200 µg/ml | $336.00 | |||
CD22 Antibody (OX97) PE | sc-53032 PE | 200 µg/ml | $349.00 |